Alfred Sandrock has sold stock and made no open-market buys since Feb 2016

Alfred W. Sandrock, Jr., M.D., Ph.D. is the President and Chief Executive Officer of Voyager Therapeutics, a position he has held since 2022, along with membership on the company's board of directors( He brings extensive expertise in biopharmaceutical drug development, having spent 23 years at Biogen where he advanced through positions of increasing responsibility, culminating in his role as Executive Vice President of Research and Development( During his tenure at Biogen, Sandrock served as Chief Medical Officer and held a seat on the Executive Committee, overseeing the discovery, development, and regulatory approval of numerous medicines including SPINRAZA®, TECFIDERA®, TYSABRI®, PLEGRIDY®, and ADUHELM™(

Sandrock earned a B.A. in human biology from Stanford University, an M.D. from Harvard Medical School, and a Ph.D. in neurobiology from Harvard University( He completed clinical training including an internship in medicine, a residency and chief residency in neurology, and a clinical fellowship in neuromuscular disease and clinical neurophysiology at Massachusetts General Hospital( In addition to his CEO role at Voyager Therapeutics, Sandrock serves on the boards of Verge Genomics, Inc., Transition Bio, Inc., and Neurimmune, Inc.(

Written by Perplexity from public sources.